Background: Increasingly, research evidence is identifying subjective cognitive decline (SCD) as a precursor for cognitive impairment and dementia. Identifying predictors of SCD is essential for understanding its utility as a preclinical indicator for impairment and especially pertinent for Hispanics/Latinos who have limited access to healthcare resources and clinical diagnostics and are disproportionally affected by Alzheimer's disease and related dementias. We extend work on predictors of Mild Cognitive Impairment (MCI) in diverse Hispanics/Latinos in the US by modeling multidomain predictors of SCD.
Method: We use data (n = 4347, average baseline age = 56.4-years) from the Hispanic Community Health Study/ Study of Latinos (HCHS/SOL; 2008-2011; Visit 1), a multisite prospective cohort study of diverse Hispanics/Latinos, and its ancillary study, the SOL-Investigation of Neurocognitive Aging (SOL-INCA; average 7-years after Visit 1). Our outcome is a composite SCD measured at SOL-INCA by averaging the component items of the Everyday Cognition (ECog-12) scale and is modeled using 37 cross-domain Visit 1 indicators, previously linked to MCI, reflecting (1) sociodemographic characteristics, (2) childhood factors, (3) acculturation factors, (4) biological and (5) behavioral markers, and (6) mental and (7) functional health factors. We use supervised machine learning (ML: Random Forest = RF; regression = ML-Reg) and standard statistical techniques (regression = Reg) for identifying leading predictors of SCD. In secondary analysis, we assess enhancement in predictive performance by accounting for Visit 1 global cognitive (GC) function.
Result: Our best performing (i.e., R-squared) ML model (ML-Reg) explained only 17% of the variance in SCD. Leading identified predictors of SCD included physical health scores, airflow obstruction, anxiety, mental health scores, Hispanic/Latino heritage, education, depression, income, and language and social acculturation. GC was predictive of SCD and explained an additional 5% of the variance.
Conclusion: Our findings indicate that multidomain factors contribute to SCD prediction, but the explained variance was relatively low. Biological markers, previously linked to MCI in our cohort, played a less significant role. Notably, the fit of the ML models for SCD was low relative to MCI specific models in the same population. Follow-up work investigates how incorporating contemporaneous measures of the factors (vs. baseline alone) may improve the predictive capacity of the ML models.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.091573 | DOI Listing |
Alzheimers Dement
December 2024
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
Background: Synaptic dysfunction plays an important role in Alzheimer's disease (AD) and cognitive decline. We investigated the association between cerebrospinal fluid (CSF) synaptic protein levels and quantitative EEG (qEEG) measures, two modalities to measure synaptic dysfunction in AD pathology. We assessed combined and independent prognostic value of both modalities for cognitive decline along the AD continuum.
View Article and Find Full Text PDFBackground: In clinical settings, the prognosis of patients with subtle cognitive complaints and no imaging evidence of neurodegeneration is often challenging, especially in conditions unrelated to Alzheimer's Disease (AD). We aimed to identify which baseline indicators can help in the clinical decision-making process of patients with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) without AD pathology, by identifying those with faster brain atrophy for their age.
Method: Young-onset SCD and MCI patients (symptoms ≤65yo) were recruited.
Alzheimers Dement
December 2024
University of California, San Diego, La Jolla, CA, USA.
Background: Increasingly, research evidence is identifying subjective cognitive decline (SCD) as a precursor for cognitive impairment and dementia. Identifying predictors of SCD is essential for understanding its utility as a preclinical indicator for impairment and especially pertinent for Hispanics/Latinos who have limited access to healthcare resources and clinical diagnostics and are disproportionally affected by Alzheimer's disease and related dementias. We extend work on predictors of Mild Cognitive Impairment (MCI) in diverse Hispanics/Latinos in the US by modeling multidomain predictors of SCD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
Background: Novel plasma markers are increasingly accepted as indicators of Alzheimer's disease and related dementia (ADRD) pathophysiology. The extent to which these markers map with clinical symptoms of disease remains unclear. A proposed early clinical symptom of ADRD is subjective cognitive decline (SCD), the experience that cognition has declined despite normal performance on objective assessment.
View Article and Find Full Text PDFRetina
January 2025
Department of Ophthalmology, Amsterdam UMC, Amsterdam, The Netherlands.
Purpose: To evaluate the presence and progression of maculopathy in patients with sickle cell disease (SCD) using Optical Coherence Tomography (OCT) and OCT-Angiography (OCTA), and to identify clinical/laboratory risk factors for progression during follow-up.
Methods: Complete ophthalmic examination, including fundoscopy and macular SD-OCT/OCTA scans, was performed in consecutive SCD-patients (HbSS/HbSβ0/HbSβ+/HbSC genotype) during baseline and follow-up visits. SCR stage was based on fundoscopy instead of the Goldberg classification, since fluorescein angiography was not routinely used.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!